Indian Pharma Paradox

Hey folks, Pratham here.

Welcome back to Paradox Weekly, a Masters' Union newsletter, where we break down the ideas, trends, and contradictions shaping business today.

In 2001, Yusuf Hamied made an offer that changed the trajectory of the global AIDS epidemic.

Cipla's managing director (now chairman) offered Africa the AIDS triple-drug cocktail for $350 per patient per year at a time when Western pharma was charging $15,000, 28 million+ Africans had HIV, and fewer than 4,000 of them could afford treatment.

Thirty-nine multinational companies dropped their lawsuit against South Africa. 

The number of Africans on treatment went from 4,000 to 8 million in a decade.

But I disagree with the version of this story we tell ourselves.

If you see the chronology of events, six years later, the AIDS Healthcare Foundation ran full-page newspaper ads in India with the headlines: "Cipla, Tell the Truth” and “Profit at What Cost? AIDS Drugs for All”.

The finding was that Cipla was charging Indian HIV patients twice more than African patients for the identical pill. 

The company that saved Africa from AIDS had not extended the same courtesy to its own country.

India supplies 47% of all generic prescriptions filled in the United States.

60% of the world's vaccines come from here.

And yet, 55 million Indians fall below the poverty line every year because they cannot pay for healthcare.

38 million of them specifically from spending on medicines.

The country that makes the world's cheapest drugs sends 38 million of its own people into poverty every year paying for them.

That’s today's paradox. 

Let me explain how.

When you walk into a chemist, 97% of what's on the shelf is technically a generic because the patent expired and the molecule is cheap to produce.

But 87% of those are "branded generics", the same compound sold under a company trade name, priced separately from every other company selling the exact same thing.

A 2026 study tested 131 drug samples across branded and generic versions and found 100% passed all pharmacopoeia quality tests, clinically identical. 

Fourteen times the price for the same pill.

Cancer drugs are worse: the branded version of Doxorubicin 50mg is 22 times the generic price.

Your doctor prescribed the expensive one because India has 600,000 medical representatives visiting clinics daily, with 60% of all pharma promotional spend going to field force activities.

The Dolo-650 case made the scale visible: Micro Labs allegedly spent ₹1,000 crore gifting doctors including televisions, international trips, and cash, just to prescribe a paracetamol tablet.

The government does have an answer. 

Jan Aushadhi stores sell unbranded generics at 50-90% below market prices, but there are over 15,000 of them against 800,000+ private pharmacies, less than 2% of outlets. 

The National Medical Commission tried mandatory generic prescribing in 2023, a policy where doctors write the molecule not the brand, and withdrew it within three weeks under industry pressure.

And I honestly think the way we talk about India's healthcare problem is completely wrong.

The default argument is that Indians can't afford medicine because India is a poor country with an underfunded healthcare system.

But India already manufactures the cheap version. 

It exists, quality-tested, and is sitting in a government store near you.

The same companies that humiliated Western pharma on behalf of Africa built a ₹1,000 crore gifting machine to make sure Indian patients never reached the cheap shelf.

The companies that saved Africa from AIDS are the same ones paying your doctor to prescribe the expensive version.

Simply put, this is not a problem of poverty, but it is one of incentives. 

A system hasn’t been built that lets cheap drugs reach the patient, because too many people between the factory and the prescription make money off the expensive version staying expensive.

I read every email.

Until next week,
Pratham